T-cells and 3D cell models for immunotherapy
Using the power of T-cells with organoids and spheroids for cancer therapy research Immunotherapy, which leverages the immune system to specifically target cancer cells, is gaining traction as an additional form of cancer treatment. These therapies include CAR T-cells (Chimeric Antigen Receptor engineered T-cells), tumor-infiltrating lymphocytes (TIL), and other genetically modified T-cells.
Enhancing T-cell recruitment and cytotoxic activity is crucial for successful cancer immunotherapy. In preclinical scientific research, 3D cell models offer advantages over 2D monolayer cultures by better mimicking the immunosuppressive tumor microenvironment (TME). For example, patient-derived organoids (PDOs) are superior to traditional 2D monolayer cultures because they better replicate the physical and chemical cues of the TME.